Search

Your search keyword '"Pissot‐Soldermann, Carole"' showing total 26 results

Search Constraints

Start Over You searched for: Author "Pissot‐Soldermann, Carole" Remove constraint Author: "Pissot‐Soldermann, Carole"
26 results on '"Pissot‐Soldermann, Carole"'

Search Results

1. Supplementary Table S2 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

2. Data from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

3. Supplementary Figures, Methods, and References from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

4. Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

6. Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies

7. Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing

8. Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood

9. Stabilizing Inactive Conformations of MALT1 as an Effective Approach to Inhibit Its Protease Activity

11. The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition

12. Optimization of the In VivoPotency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood

13. Discovery of Potent, Highly Selective, and In VivoEfficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing

14. The T‐cell fingerprint of MALT1 paracaspase revealed by selective inhibition.

15. Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

18. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors

19. Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial

20. Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

21. Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

26. A short and concise asymmetric synthesis of hamigeran B.

Catalog

Books, media, physical & digital resources